EA033686B1 - Гетероциклические соединения, применимые в качестве модуляторов tnf-альфа - Google Patents

Гетероциклические соединения, применимые в качестве модуляторов tnf-альфа Download PDF

Info

Publication number
EA033686B1
EA033686B1 EA201890165A EA201890165A EA033686B1 EA 033686 B1 EA033686 B1 EA 033686B1 EA 201890165 A EA201890165 A EA 201890165A EA 201890165 A EA201890165 A EA 201890165A EA 033686 B1 EA033686 B1 EA 033686B1
Authority
EA
Eurasian Patent Office
Prior art keywords
chloro
amino
ethyl
quinolin
pyrimidin
Prior art date
Application number
EA201890165A
Other languages
English (en)
Russian (ru)
Other versions
EA201890165A1 (ru
Inventor
Hai-Yun Xiao
T G Murali Dhar
Ning Li
Jingwu Duan
Bin Jiang
Zhonghui Lu
Khehyong Ngu
William J Pitts
Joseph TINO
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EA201890165A1 publication Critical patent/EA201890165A1/ru
Publication of EA033686B1 publication Critical patent/EA033686B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EA201890165A 2015-08-03 2016-08-02 Гетероциклические соединения, применимые в качестве модуляторов tnf-альфа EA033686B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562200424P 2015-08-03 2015-08-03
PCT/US2016/045110 WO2017023905A1 (en) 2015-08-03 2016-08-02 Heterocyclic compounds useful as modulators of tnf alpha

Publications (2)

Publication Number Publication Date
EA201890165A1 EA201890165A1 (ru) 2018-07-31
EA033686B1 true EA033686B1 (ru) 2019-11-15

Family

ID=56618285

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890165A EA033686B1 (ru) 2015-08-03 2016-08-02 Гетероциклические соединения, применимые в качестве модуляторов tnf-альфа

Country Status (22)

Country Link
US (1) US10865191B2 (enExample)
EP (1) EP3331871A1 (enExample)
JP (1) JP6955482B2 (enExample)
KR (1) KR102697810B1 (enExample)
CN (1) CN108137547B (enExample)
AR (1) AR105575A1 (enExample)
AU (1) AU2016302144B2 (enExample)
BR (1) BR112018001960A2 (enExample)
CA (1) CA2994717A1 (enExample)
CL (1) CL2018000293A1 (enExample)
CO (1) CO2018002061A2 (enExample)
EA (1) EA033686B1 (enExample)
HK (1) HK1252623A1 (enExample)
IL (1) IL257154A (enExample)
MA (1) MA43512A (enExample)
MX (1) MX375341B (enExample)
PE (1) PE20181366A1 (enExample)
SG (1) SG10201911831RA (enExample)
TW (1) TW201718536A (enExample)
UY (1) UY36838A (enExample)
WO (1) WO2017023905A1 (enExample)
ZA (1) ZA201800716B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104291A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
UY36629A (es) 2015-04-17 2016-11-30 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
EP3286195A1 (en) 2015-04-17 2018-02-28 AbbVie Inc. Indazolones as modulators of tnf signaling
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
HUE048902T2 (hu) 2015-08-03 2020-08-28 Glenmark Pharmaceuticals Sa Új ROR gamma modulátor vegyületek
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
JOP20190257A1 (ar) * 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
JP2021512898A (ja) * 2018-02-09 2021-05-20 アメリカ合衆国 複素環ｐ２ｙ１４受容体拮抗薬
CN108658977A (zh) * 2018-04-12 2018-10-16 苏州康润医药有限公司 一种7-溴-1,5-萘啶-3-甲酸的合成方法
WO2021233861A1 (en) 2020-05-19 2021-11-25 Bayer Aktiengesellschaft Azabicyclic(thio)amides as fungicidal compounds
BR112022024413A2 (pt) 2020-06-10 2023-02-07 Bayer Ag Heterociclos substituídos com azabiciclila como fungicidas inovadores
WO2021262596A1 (en) 2020-06-22 2021-12-30 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function
AU2021297465A1 (en) 2020-06-27 2023-03-02 Crescenta Biosciences Novel cell metabolism modulating compounds and uses thereof
JP2023550830A (ja) * 2020-11-27 2023-12-05 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｐ２ｘ３阻害剤としての（アザ）キノリン４－アミン誘導体
US11673876B2 (en) 2020-12-22 2023-06-13 Mekanistic Therapeutics Llc Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors
TW202320766A (zh) * 2021-09-29 2023-06-01 大陸商上海海和藥物研究開發股份有限公司 一類具有吡啶并六員環結構的ｓｏｓ１抑制劑
US20240425501A1 (en) * 2021-10-21 2024-12-26 Sanjita Sasmal Novel bicyclic heteroaryl derivatives as sos1:kras proteinprotein interaction inhibitors
US12138243B2 (en) 2021-12-31 2024-11-12 Crescenta Biosciences Antiviral use of FABP4 modulating compounds
CN114605409B (zh) * 2022-04-01 2024-04-02 苏州睿尔思科技有限公司 一种4-羟基-1,5-萘啶类配体的生产制备方法
CN114751858B (zh) * 2022-04-20 2023-09-12 沈阳药科大学 含有喹啉基的氨甲环酸衍生物及其制备与应用
CN117024404A (zh) * 2022-05-10 2023-11-10 四川汇宇制药股份有限公司 苯并吡啶衍生物及其用途
US20250084063A1 (en) * 2023-08-18 2025-03-13 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
TW202542130A (zh) * 2024-01-05 2025-11-01 美商露點治療股份有限公司 胺基喹啉化合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155121A2 (en) * 2008-05-30 2009-12-23 Amgen Inc. Inhibitors of pi3 kinase
WO2014009295A1 (en) * 2012-07-13 2014-01-16 Ucb Pharma S.A. Imidazopyridine derivatives as modulators of tnf activity

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US856095A (en) * 1906-09-01 1907-06-04 Railway Safety Signal Company Electric semaphore.
PH25124A (en) 1987-03-17 1991-02-19 Hoechst Roussel Pharma Substituted 9-amino-tetrahydro acridines and related compounds
DE3917232A1 (de) * 1989-05-26 1990-11-29 Basf Ag 4-arylmethamino-2,3-dialkyl-chinoline, ihre verwendung und daraus hergestellte arzneimittel
EP1390349B1 (en) 2001-05-31 2012-07-25 Sanofi Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
AU2002341715A1 (en) * 2001-09-17 2003-04-01 Bristol-Myers Squibb Company Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
US7294624B2 (en) 2001-12-20 2007-11-13 Bristol Myers Squibb Company Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases
HUP0105406A3 (en) 2001-12-21 2003-12-29 Sanofi Aventis Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
JP2007500689A (ja) 2003-07-31 2007-01-18 サノフイ−アベンテイス アミノキノリン誘導体およびアデノシンａ３リガンドとしてのそれらの使用
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
US9120749B2 (en) * 2010-07-30 2015-09-01 Oncotherapy Science, Inc. Quinoline derivatives and MELK inhibitors containing the same
CA2874303C (en) 2012-06-11 2020-10-13 Ucb Biopharma Sprl Tnf -alpha modulating benz imidazoles
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
EA201591746A1 (ru) 2013-03-14 2016-08-31 КОНВЕРДЖЕН ЭлЭлСи Способы и композиции для ингибирования бромодомен-содержащих белков
HUE048902T2 (hu) 2015-08-03 2020-08-28 Glenmark Pharmaceuticals Sa Új ROR gamma modulátor vegyületek
AR105556A1 (es) 2015-08-03 2017-10-18 Hoffmann La Roche Derivados de etinilo
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
WO2017167993A1 (en) 2016-04-01 2017-10-05 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives as modulators of tnf activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155121A2 (en) * 2008-05-30 2009-12-23 Amgen Inc. Inhibitors of pi3 kinase
WO2014009295A1 (en) * 2012-07-13 2014-01-16 Ucb Pharma S.A. Imidazopyridine derivatives as modulators of tnf activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DEGORCE ET AL: "Discovery of novel 3-quinoline carboxamides as potent, selective and orally bioavailable inhibitors of Atexia Telangiectasia mutated (ATM) kinase", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, 3 June 2016 (2016-06-03), pages 6281 - 6292, XP002762230 *
OCHIANA ET AL: "Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei", CHEMICAL BIOLOGY AND DRUG DESIGN, vol. 85, 1 May 2015 (2015-05-01), pages 549 - 564, XP002762229 *
STADERINI ET AL: "Lewis acid-catalyzed generation of C-C and C-N bonds on pi-deficient heterocyclic substrates", ADVANCED SYNTHESIS AND CATALYSIS, vol. 357, no. 1, 8 December 2014 (2014-12-08), pages 185 - 195, XP002762228 *

Also Published As

Publication number Publication date
PE20181366A1 (es) 2018-08-27
MA43512A (fr) 2018-11-07
AU2016302144B2 (en) 2020-10-08
IL257154A (en) 2018-03-29
EP3331871A1 (en) 2018-06-13
CN108137547B (zh) 2021-11-12
CL2018000293A1 (es) 2018-07-13
UY36838A (es) 2017-01-31
CN108137547A (zh) 2018-06-08
KR102697810B1 (ko) 2024-08-21
ZA201800716B (en) 2019-07-31
CA2994717A1 (en) 2017-02-09
SG10201911831RA (en) 2020-02-27
AR105575A1 (es) 2017-10-18
BR112018001960A2 (pt) 2018-09-18
US20180222883A1 (en) 2018-08-09
CO2018002061A2 (es) 2018-06-20
EA201890165A1 (ru) 2018-07-31
KR20180031772A (ko) 2018-03-28
US10865191B2 (en) 2020-12-15
WO2017023905A1 (en) 2017-02-09
MX2018001054A (es) 2018-07-06
TW201718536A (zh) 2017-06-01
HK1252623A1 (zh) 2019-05-31
MX375341B (es) 2025-03-06
JP6955482B2 (ja) 2021-10-27
JP2018525379A (ja) 2018-09-06
AU2016302144A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
KR102697810B1 (ko) Tnf 알파의 조정제로서 유용한 헤테로시클릭 화합물
KR102891608B1 (ko) Irak 분해제 및 이의 용도
CN112204009B (zh) 整合应激通路的调节剂
KR102001745B1 (ko) 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물
AU2014315457B2 (en) Compounds useful as immunomodulators
KR102641263B1 (ko) 헤테로아릴 치환된 아미노피리딘 화합물
AU2015335703B2 (en) Carbazole derivatives
JP2024505652A (ja) Ｃｂｌ－ｂ阻害剤としてのラクタム
JP2019530695A (ja) 置換１Ｈ−イミダゾ［４，５−ｂ］ピリジン−２（３Ｈ）−オン及びＧＬＵＮ２Ｂ受容体調節因子としてのそれらの使用
CA2935329A1 (en) Heteroaryl substituted nicotinamide compounds
EP3313840A1 (en) Heteroaryl substituted aminopyridine compounds
KR20180108822A (ko) Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸
TW201317215A (zh) 具治療作用之組成物及其使用方法
JP2014524886A (ja) カリウムチャネル遮断剤としてのアミン誘導体
JP6592512B2 (ja) 三環式アトロプ異性体の化合物
JP6392352B2 (ja) リーシュマニア症などの寄生虫病を処置するための原生動物のプロテアソーム阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体
EA031310B1 (ru) Производные пиперидина и азепина как модуляторы рецептора прокинетицина
HK40044910B (en) Modulators of the integrated stress pathway
HK40017188B (en) Pd-1/pd-l1 inhibitors
HK1238642A1 (en) Carbazole derivatives
HK1238642B (en) Carbazole derivatives
EP3475270A1 (en) Heteroaryl substituted aminopyridine compounds

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM